Vaxcyte, Inc. 4

Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc., exercised 17,000 stock options at $24.79 and sold 17,000 common shares at about $55.00 per share on August 5, 2026 under a Rule 10b5-1 plan.

On August 5, 2026, Vaxcyte, Inc. Chief Technical Ops Officer Harpreet S. Dhaliwal exercised 17,000 stock options at $24.79 per share, acquiring 17,000 shares of common stock, and on the same date sold 17,000 shares of common stock at a weighted-average price of $55.004 per share under a pre-established Rule 10b5-1 trading plan, resulting in a post-transaction direct ownership of 76,756 shares (including 780 shares acquired earlier under the Employee Stock Purchase Plan); the option was fully vested, and the net effect was a cashless or near-cashless exercise and sale with no change in total share count from this paired transaction aside from prior ESPP accumulation.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001886794-26-000008

Alert Tier

6